Navigation Links
Brandeis scientists win prestigious prize for circadian rhythms research
Date:3/21/2012

Two distinguished Brandeis researchers, whose long-standing collaboration led to pioneering discoveries about the workings of the biological clock and its role in circadian rhythms, today were awarded the prestigious Canada Gairdner Award, that nation's foremost international scientific honor.

Michael Rosbash, the Peter and Patricia Gruber Professor of Neuroscience and director of the Brandeis' National Center for Behavioral Genomics, and Professor Emeritus of Biology Jeffrey C. Hall were given the award "to recognize and reward the achievements of medical researchers whose work contributes significantly to improving the quality of human life."

They share the Canada Gairdner Award with Professor Michael W. Young of Rockefeller University in New York. This is the third major award for the trio stemming from their groundbreaking research into circadian rhythms, using the fruit fly Drosophila melanogaster. Last year, they were awarded the Louisa Gross Horwitz Prize from Columbia University. In 2009, the Peter and Patricia Gruber Foundation awarded them its Neuroscience Prize.

Rosbash, in accepting the award today, said: "It's a very flattering honor, in large part because of the wonderful group of people who go before us, who have won the Canada Gairdner Awards in the past. I am humbled by being included in their company."

President Fred Lawrence congratulated the two Brandeis scientists and their colleague. "We are extremely proud of them and the research that was conducted on this campus," he said. "This was extraordinary work that holds the promise of improving human life, and it represents the best of Brandeis."

The Gairdner Foundation in Toronto began giving awards in 1959 to recognize and reward the world's most creative and accomplished biomedical scientists. Of 298 individuals from 13 countries who have been honored, 76 have subsequently won the Nobel Prize.

"The Canada Gairdner Award has a big role to
'/>"/>

Contact: Susan Chaityn Lebovits
lebovits@brandeis.edu
781-736-4027
Brandeis University
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Brandeis and Smart Balance team up to advance heart-healthy research
2. NIH grant will boost electron microscopy at Brandeis
3. Brandeis wins $1 million Keck Foundation grant to research active matter
4. Brandeis study shows economic impact of dengue virus in Americas
5. Brandeis researchers use lasers, custom microscope to show gene splicing process in real time
6. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
7. Scientists identify novel inhibitor of human microRNA
8. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
9. MU scientists go green with gold, distribute environmentally friendly nanoparticles
10. Scientists identify gene that may contribute to improved rice yield
11. Scientists discover why a mothers high-fat diet contributes to obesity in her children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... first time, researchers have discovered a disease mechanism that links ... of ALS -- and points to a possible therapeutic target. ... in the journal Nature Neuroscience . ALS is ... and death within three to five years of diagnosis. ...
... ongoing concern about plastic waste accumulating in municipal landfills, ... are reporting development of a new ultra-light biodegradable foam ... in milk and ordinary clay. The new substance could ... products, they report in the ACS, Biomacromolecules , ...
... ever on the verge of suicide, requiring the close ... cells from pulling the trigger. This self-destructive tendency can ... cells are permitted to kill themselves, but it can ... memories, for instance. Rockefeller University scientists are parsing this ...
Cached Biology News:Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3'Reaper' protein strikes at mitochondria to kill cells 2
(Date:7/28/2015)... 28, 2015  Kerastem Technologies announce that the Company ... FDA Center For Biologics Evaluation and Research (CBER) Office ... clinical trial investigating the safety and feasibility of the ... male pattern baldness (androgenic alopecia). The phase ... clinical work in Europe and ...
(Date:7/28/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results for ... "Orenitram ®  sales grew nearly 300% as compared ... product was first launched," said Roger Jeffs, Ph.D., ... growth in Orenitram sales was due to an ...
(Date:7/27/2015)... Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), ... treatment of cancer, today provides the following financial update. ... $1,000,000 unit offering private placement.  This financing is a ... at a price of $0.06 per unit.  Each unit ... share purchase warrant.  Each whole warrant is exercisable into ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Quest PharmaTech Closes $1,000,000 Private Placement 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged ... of human viral and other infectious diseases, today reported unaudited ... 31, 2008. At December 31, 2008, Idenix,s cash, cash equivalents ... , ...
... Audit Confirms Responsible Use. , ... Wilmington, DE (Vocus) ... have verified its plant biotechnology research and development processes are in ... its North American operations. The ETS third-party audit confirms that ...
... ON LICENSING, FUNDING, ACQUISITION AND INFORMATION MANAGEMENT INITIATIVES TO ACCELERATE ... Sinobiomed Inc. ("Sinobiomed," or "the Company") (OTC Bulletin Board: SOBM) ... management team to accelerate the Company,s growth. The new management ... , Dr. Anchie ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7DuPont Biotech Stewardship Program Gains External Certification 2DuPont Biotech Stewardship Program Gains External Certification 3Sinobiomed Announces New Executive Team 2Sinobiomed Announces New Executive Team 3
SRY (sex determining region Y)-box 10...
Complement C1r [Human]...
biotin-4-fluorescein...
... LVF-CUV-ADP, FHS-LVF and CVD-Diffuse We've combined ... Filters to create the world's first notch ... adjustable bandpass. Each filter features an excellent ... These filters -- with interference coatings ...
Biology Products: